Xilio Therapeutics (XLO) Equity Average (2020 - 2026)

Xilio Therapeutics has disclosed Equity Average across 7 years of filings, most recently posting $53.9 million for Q1 2026.

• Equity Average for Q1 2026 came in at $53.9 million, up 281.01% year-over-year; the trailing twelve-month figure through Mar 2026 was $53.9 million (up 281.01% YoY), and the FY2025 annual result was $26.4 million, down 2.86% from the prior year.
• Equity Average came in at $53.9 million for Q1 2026 at Xilio Therapeutics, up from $13.6 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $175.8 million in Q1 2022 to a low of -$513000.0 in Q3 2025.
• The 5-year median for Equity Average is $44.7 million (2023), against an average of $62.1 million.
• Across the five-year window, Equity Average soared 373.61% in 2022 and tumbled 101.89% in 2025, its largest moves.
• Xilio Therapeutics' Equity Average stood at $116.0 million in 2022, then sank by 61.49% to $44.7 million in 2023, then plunged by 56.82% to $19.3 million in 2024, then decreased by 29.54% to $13.6 million in 2025, then jumped by 296.71% to $53.9 million in 2026.
• The last three Equity Average figures came in at $53.9 million (Q1 2026), $13.6 million (Q4 2025), and -$513000.0 (Q3 2025), per Business Quant data.